FDA Inspection 1122803 — Piedmont Reproductive Endocrinology Group, Pa

Piedmont Reproductive Endocrinology Group, Pa — FEI 3005144056

The FDA completed an inspection of Piedmont Reproductive Endocrinology Group, Pa on January 28, 2020 in Greenville, SC. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
January 28, 2020
Fiscal Year
2020
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Greenville, SC (United States)